echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Betta Pharmaceuticals' CDK4/6 inhibitor was approved for clinical use

    Betta Pharmaceuticals' CDK4/6 inhibitor was approved for clinical use

    • Last Update: 2021-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the information published by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, BPI-16350 Capsules of Betta Pharmaceuticals has obtained two clinical trials implied licenses and plans to develop treatments for breast cancer
    .


    Public information shows that BPI-16350 is a CDK4/6 inhibitor under development and belongs to a class 1 new drug.


    Screenshot source: CDE official website

    According to the announcement of Betta Pharmaceuticals, BPI-16350 is a CDK4/6 inhibitor independently developed by the company.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.